Spero Therapeutics, Inc.

SPRO

Spero Therapeutics, Inc.

SPRO

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-05-04Shares Purchased (TTM):0Shares Sold (TTM):202,259

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:20,359,684Shares Outstanding:57,281,570Institutional Ownership Pct.:35.54%

Earnings Market Reaction:

Filing Date:2026-08-12Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	51	56	40	49	31	49	53	76	64	82	76	94
Other Receivables	-	0	0	2	2	1	3	3	5	5	2	3
Prepaid Expense And Other Assets Current	1	1	2	1	1	2	2	2	3	4	4	5
Assets Current	52	58	67	52	59	75	107	132	122	140	131	102
Operating Lease Right Of Use Asset	1	1	1	2	3	3	3	3	4	4	4	4
Property Plant And Equipment Net	-	-	-	-	-	-	0	0	0	0	0	0
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	53	59	69	54	62	78	111	135	150	168	182	107
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	0	0	1	1	1	2	7	6	3	3	1	1
Operating Lease Liability Current	2	2	2	2	2	2	2	2	2	2	2	2
Taxes Payable Current	0	0	0	0	0	0	0	0	0	0	0	2
Deferred Revenue Current	-	-	0	0	0	0	0	1	4	3	2	14
Liabilities Current	8	5	9	14	15	29	49	49	46	42	37	25
Operating Lease Liability Noncurrent	0	1	1	1	2	2	3	3	3	4	4	4
Deferred Revenue Noncurrent	-	-	0	13	13	13	12	12	9	10	11	24
Other Long Term Debt Noncurrent	0	0	0	-	-	-	0	0	0	0	0	0
Liabilities	9	6	10	28	29	44	64	70	69	71	75	53
Stockholders Equity Inclu…
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	512	511	510	509	508	507	506	504	502	500	498	496
Retained Earnings Accumulated Deficit	-468	-458	-451	-483	-475	-474	-460	-439	-422	-404	-391	-442
Stockholders Equity	44	53	59	26	33	34	46	66	81	96	107	54
Liabilities And Stockholders Equity	53	59	69	54	62	78	111	135	150	168	182	107
Accumulated Other Comprehensive Income Loss Net Of…	-	-	-	-	-	-	-	-	-	-	0	0
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	240	120	120	120	120	120	120	120	120	120	120	120
Common Stock Shares Issued	58	58	56	56	56	56	55	54	54	54	53	53
Shares Outstanding	58	58	56	56	56	56	55	54	54	54	53	53

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	15.57%	-9.84%	-52.05%	-	-	-	-	-	-	-	-	-
2025	262.32%	321.74%	233.33%	-8.90%	-13.14%	2.97%	-7.38%	-3.69%	-10.25%	16.03%	17.72%	20.25%
2024	-13.27%	-19.14%	-19.14%	2.24%	-2.24%	-0.75%	-6.40%	-12.00%	-31.44%	-12.33%	-24.30%	229.07%
2023	-	-	-	-	-	-	18.92%	28.83%	31.08%	-0.60%	-1.81%	-14.46%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	6.12	10.50	7.59	3.83	3.97	2.56	2.19	2.68	2.68	3.35	3.53	4.01
Quick Ratio	6.03	10.23	7.40	3.74	3.89	2.51	2.15	2.64	2.61	3.26	3.42	3.80
Working Capital	43.16M	52.12M	58.42M	38.67M	44.46M	45.56M	58.20M	82.53M	76.59M	98.33M	94.06M	76.76M
Leverage & Debt
Debt to Equity	0.19	0.11	0.17	1.04	0.89	1.30	1.40	1.06	0.86	0.74	0.71	0.99
Debt Ratio	0.16	0.10	0.14	0.51	0.47	0.56	0.58	0.52	0.46	0.43	0.41	0.50
Efficiency & Turnover
Asset Turnover TTM	1.17	0.98	0.81	-0.14	-0.12	-0.02	0.00	-0.07	0.14	0.07	0.01	0.29
Per Share Metrics
Diluted EPS TTM	0.13	0.27	0.15	-0.78	-0.96	-1.26	-1.27	0.06	0.32	0.44	0.43	1.73
Free Cash Flow Per Share TTM	-0.00	0.13	-0.23	-0.42	-0.51	-0.60	-0.43	-0.32	-0.27	-0.27	-0.63	0.55
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	8.98%	20.14%	8.69%	352.42%	434.93%	2,452.35%	-19,773.85%	13.89%	89.10%	217.76%	2,302.36%	-12.59%
Net Profit Margin TTM	11.01%	22.72%	11.79%	329.99%	405.48%	2,308.50%	-18,481.40%	-44.19%	99.98%	234.57%	2,444.37%	367.11%
Growth Metrics
Net Revenue Growth (1Y)	-607.30%	-2,319.06%	19,489.22%	67.09%	-175.72%	-130.29%	-60.24%	-132.00%	1,165.07%	1,418.57%	-62.72%	-2,645.80%
Net Income Growth (1Y)	-113.77%	-121.84%	-112.50%	-1,347.82%	-407.08%	-398.09%	-400.65%	-96.15%	-78.91%	-64.53%	-50.87%	-189.06%
EPS Growth (1Y)	-113.31%	-121.11%	-112.06%	-1,300.02%	-395.74%	-388.12%	-393.22%	-96.25%	-79.45%	-65.19%	-64.96%	-160.62%
Valuation Metrics
P/E TTM	17.35	8.80	15.23	-2.41	-3.03	-0.57	-0.81	20.65	4.02	3.93	3.40	0.70
P/B TTM	2.90	2.53	2.21	3.99	4.95	1.18	1.21	1.11	0.87	0.96	0.72	1.19
P/S TTM	1.91	2.00	1.80	-7.97	-12.29	-13.19	150.02	-9.12	4.02	9.23	83.04	2.57
Market Cap	128.11M	134.04M	130.53M	105.81M	162.48M	39.87M	55.66M	72.53M	70.15M	92.06M	77.47M	63.78M
Enterprise Value	77.34M	77.91M	90.26M	57.19M	131.28M	-9.02M	2.77M	-3.76M	6.62M	9.79M	1.14M	-30.05M
Calculated Values
Free Cash Flow TTM	-286.00K	7.24M	-12.62M	-23.67M	-28.33M	-33.38M	-23.44M	-17.54M	-14.38M	-14.20M	-33.00M	28.98M
Net Debt	-50.77M	-56.13M	-40.27M	-48.62M	-31.19M	-48.89M	-52.89M	-76.29M	-63.53M	-82.27M	-76.33M	-93.83M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-04Sale

Owner: Rajavelu, Esther

Title: See Remarks

Shares: 25,240

Price/Share: $2.51

Value: $63,352.40

Shares Owned: 986,851

Relationship: Officer

Ownership: Direct

2026-02-06Sale

Owner: Rajavelu, Esther

Title: See Remarks

Shares: 87,917

Price/Share: $2.36

Value: $207,484.12

Shares Owned: 1,012,091

Relationship: Officer

Ownership: Direct

2026-02-06Sale

Owner: Keutzer, Timothy

Title: Chief Operating Officer

Shares: 18,652

Price/Share: $2.36

Value: $44,018.72

Shares Owned: 742,506

Relationship: Officer

Ownership: Direct

2026-02-04Sale

Owner: Keutzer, Timothy

Title: Chief Operating Officer

Shares: 3,471

Price/Share: $2.24

Value: $7,775.04

Shares Owned: 761,158

Relationship: Officer

Ownership: Direct

2026-02-02Sale

Owner: Rajavelu, Esther

Title: See Remarks

Shares: 18,442

Price/Share: $2.20

Value: $40,572.40

Shares Owned: 1,100,008

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-04	Rajavelu, Esther	Officer	See Remarks	Direct	Sale	25,240	2.51	$63,352.40	986,851	4
2026-02-06	Rajavelu, Esther	Officer	See Remarks	Direct	Sale	87,917	2.36	$207,484.12	1,012,091	4
2026-02-06	Keutzer, Timothy	Officer	Chief Operating Officer	Direct	Sale	18,652	2.36	$44,018.72	742,506	4
2026-02-04	Keutzer, Timothy	Officer	Chief Operating Officer	Direct	Sale	3,471	2.24	$7,775.04	761,158	4
2026-02-02	Rajavelu, Esther	Officer	See Remarks	Direct	Sale	18,442	2.20	$40,572.40	1,100,008	4
2025-11-07	Rajavelu, Esther	Officer	See Remarks	Direct	Sale	40,270	2.37	$95,439.90	869,450	4
2025-08-28	Keutzer, Timothy	Officer	Chief Operating Officer	Direct	Sale	1,695	1.97	$3,339.15	739,744	4
2025-08-28	Mahadevia, Ankit	Director	-	Direct	Sale	6,572	1.97	$12,946.84	703,294	4
2025-02-05	Mahadevia, Ankit	Director	-	Direct	Sale	69,219	0.78	$53,990.82	689,866	4
2025-02-05	Shukla, Sath	Officer	CEO & President	Direct	Sale	155,333	0.78	$121,159.74	1,736,883	4
2025-02-05	Rajavelu, Esther	Officer	CFO & CBO	Direct	Sale	20,689	0.78	$16,137.42	724,720	4
2025-02-05	Keutzer, Timothy	Officer	Chief Operating Officer	Direct	Sale	56,537	0.78	$44,098.86	741,439	4
2024-11-08	Rajavelu, Esther	Officer	CFO & CBO	Direct	Sale	17,245	1.30	$22,418.50	379,270	4
2024-08-27	Mahadevia, Ankit	Director	-	Direct	Sale	5,912	1.35	$7,981.20	759,085	4
2024-08-27	Shukla, Sath	Officer	CEO & President	Direct	Sale	2,757	1.35	$3,721.95	1,140,809	4
2024-08-27	Keutzer, Timothy	Officer	Chief Operating Officer	Direct	Sale	2,213	1.35	$2,987.55	531,837	4
2024-08-05	Shukla, Sath	Officer	CEO and President	Direct	Sale	17,641	1.31	$23,109.71	1,143,566	4
2024-02-05	Shukla, Sath	Director,Officer	CEO and President	Direct	Sale	45,093	1.45	$65,384.85	1,176,007	4
2024-02-02	Mahadevia, Ankit	Director	-	Direct	Sale	63,795	1.37	$87,399.15	744,997	4
2024-02-02	Keutzer, Timothy	Officer	Chief Operating Officer	Direct	Sale	30,971	1.36	$42,120.56	534,050	4
2024-02-02	Joseph, Tamara L	Officer	Chief Legal Officer	Direct	Sale	30,906	1.37	$42,341.22	531,615	4
2024-02-02	Hamed, Kamal	Officer	Chief Medical Officer	Direct	Sale	28,075	1.37	$38,462.75	788,117	4
2023-09-13	Hamed, Kamal	Officer	Chief Medical Officer	Direct	Sale	39,496	1.27	$50,159.92	576,461	4
2023-08-29	Shukla, Sath	Director,Officer	CEO and President	Direct	Sale	4,163	1.30	$5,411.90	572,500	4
2023-08-28	Joseph, Tamara L	Officer	Chief Legal Officer	Direct	Sale	1,854	1.26	$2,336.04	322,790	4
2023-08-28	Mahadevia, Ankit	Director	-	Direct	Sale	9,040	1.26	$11,390.40	788,792	4
2023-08-28	Keutzer, Timothy	Officer	Chief Development Officer	Direct	Sale	1,854	1.26	$2,336.04	325,290	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

35.54%

Inst. Shares: 20,359,684

Shares Outstanding: 57,281,570

2025-12-31

37.37%

Inst. Shares: 20,935,352

Shares Outstanding: 56,020,363

2025-09-30

19.89%

Inst. Shares: 11,191,804

Shares Outstanding: 56,280,844

2025-06-30

19.52%

Inst. Shares: 10,935,346

Shares Outstanding: 56,026,767

2025-03-31

32.64%

Inst. Shares: 18,072,865

Shares Outstanding: 55,376,188

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	20,359,684	57,281,570	35.54%
2025-12-31	20,935,352	56,020,363	37.37%
2025-09-30	11,191,804	56,280,844	19.89%
2025-06-30	10,935,346	56,026,767	19.52%
2025-03-31	18,072,865	55,376,188	32.64%
2024-12-31	14,575,320	54,037,917	26.97%
2024-09-30	11,242,045	54,124,862	20.77%
2024-06-30	12,791,190	53,957,766	23.71%
2024-03-31	12,075,479	53,524,037	22.56%
2023-12-31	12,897,087	52,703,467	24.47%
2023-09-30	13,345,740	52,710,280	25.32%
2023-06-30	13,568,885	52,571,813	25.81%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Spero Therapeutics, Inc. (SPRO) — SEC Financial Statements & Analysis

Spero Therapeutics, Inc. (SPRO) is a pharmaceutical preparations company, incorporated in DE. Spero Therapeutics, Inc. trades on Nasdaq as: SPRO. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Spero Therapeutics, Inc. reported a -607.30% year-over-year revenue growth, a Debt-to-Equity ratio of 0.19x, a Price-to-Sales (P/S) ratio of 1.91x (TTM), a Price-to-Book (P/B) ratio of 2.90x (TTM), at a market cap of $128.11M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -607.30%
Debt To Equity: 0.19x
P/S TTM: 1.91x
P/B TTM: 2.90x
Market Cap: $128.11M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Spero Therapeutics, Inc. in?

Spero Therapeutics, Inc. (SPRO) operates in the Pharmaceutical Preparations industry.

What is SPRO's market cap?

Spero Therapeutics, Inc. (SPRO) has a market capitalization of $128.11M as of 2026-06-30.

What is SPRO's P/E ratio?

Spero Therapeutics, Inc. (SPRO)'s trailing twelve month P/E ratio is 17.35x as of 2026-06-30.

What exchange does SPRO trade on?

Spero Therapeutics, Inc. (SPRO) trades on the Nasdaq.

Where is Spero Therapeutics, Inc. incorporated?

Spero Therapeutics, Inc. is incorporated in DE.